Eslicarbazepine Acetate Tablet
Product Images NDC 59746-717

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Eslicarbazepine Acetate (NDC 59746-717). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Jubilant Cadista Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

200-30s (200 30s)

Label for Eslicarbazepine Acetate Tablets 200 mg oral tablets by Jubilant Cadista Pharmaceuticals Inc. The label indicates a 30-tablet package with instructions for pharmacist dispensing and storage conditions. The product is prescription-only and made in India, marketed by Jubilant Cadista Pharmaceuticals Inc., Yardley, PA, USA.*

FDA Label Image

400-30s (400 30s)

Label for Eslicarbazepine Acetate Tablets 400 mg oral tablets by Jubilant Cadista Pharmaceuticals Inc. The label indicates a 30 tablet count with instructions to see the package insert for dosage information. It includes storage conditions, usage warnings, and barcode and serialization details.*

FDA Label Image

600-60s (600 60s)

Label for Eslicarbazepine Acetate Tablets, 600 mg oral tablets, marketed by Jubilant Cadista Pharmaceuticals Inc. The label includes dosage instructions to see package insert, storage conditions, tablet count of 60, and dispensing guidance for pharmacists. It also shows barcodes, batch, lot, expiry, and serial number placeholders.*

FDA Label Image

800-30s (800 30s)

Label for Eslicarbazepine Acetate Tablets 800 mg, oral tablets in a carton of 30 tablets. The label shows the drug name, strength, and dosage form, along with storage instructions and manufacturer information from Jubilant Cadista Pharmaceuticals Inc. It includes a barcode, NDC 59746-720-30, and a note for pharmacists to dispense the medication guide to patients.*

FDA Label Image

Figure1 (Fig01)

A chart displaying fold change and 90% confidence intervals for eslicarbazepine acetate relative to reference under various conditions including age (>= 65 years), gender (female), hepatic impairment (mild, moderate, severe), and renal impairment (mild, moderate, severe). Recommendations for dose adjustments are listed alongside, indicating no dose adjustments for most conditions except dose reduction recommended for moderate and severe renal impairment.*

FDA Label Image

Figure2 (Fig02)

A chart showing the fold change and 90% confidence interval (CI) for various drugs relative to eslicarbazepine acetate. The chart includes drugs such as carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, topiramate, and valproate, with recommendations on dose adjustments when used with eslicarbazepine acetate tablets.*

FDA Label Image

Figure04 (Fig04)

A chart showing the Kaplan-Meier (KM) estimate of exit rate percentages with 95% confidence intervals for eslicarbazepine acetate tablets at doses of 1,200 mg and 1,600 mg, comparing results from two studies and historical controls. Study 1 and Study 2 data points indicate sample sizes for each dose group.*

FDA Label Image

Figure05 (Fig05)

A bar chart comparing the proportion of patients (%) by reduction in seizure frequency from baseline (%) for eslicarbazepine acetate tablets at 800 mg and 1200 mg doses versus placebo. The x-axis shows categories of seizure frequency reduction (Worse, 0 to < 25%, 25 to < 50%, 50 to < 75%, 75 to 100%), and the y-axis shows the proportion of patients in each category. Each category displays three bars representing placebo, 800 mg, and 1200 mg eslicarbazepine acetate groups.*

FDA Label Image

Figure3a (Fig3a)

A chart depicting fold change and 90% confidence intervals for various antiepileptic drugs (AEDs) relative to a reference, with corresponding dose adjustment recommendations. Drugs listed are Carbamazepine, Gabapentin, Lamotrigine, Levetiracetam, Phenobarbital, Phenytoin, Topiramate, and Valproate. Recommendations include potential dose adjustments or monitoring for Carbamazepine and Phenytoin, while others show no changes needed.*

FDA Label Image

Figure3b (Fig3b)

A chart depicting fold change and 90% confidence intervals for various medications when taken with eslicarbazepine acetate. It includes non-AEDs (Digoxin, Metformin), statins (Simvastatin, Rosuvastatin), oral contraceptives (Ethinylestradiol, Levonorgestrel), and Warfarin enantiomers (S-Warfarin, R-Warfarin). Recommendations related to dosage adjustments and monitoring are aligned with the medication changes shown.*

FDA Label Image

Imprint (Imprint)

Eslicarbazepine Acetate 400 mg oral tablet blister pack. The packaging shows each tablet individually sealed in a silver foil blister. The label includes the product name Eslicarbazepine Acetate and the strength of 400 mg, produced by Jubilant Cadista Pharmaceuticals Inc.*

FDA Label Image

Imprint1 (Imprint1)

Eslicarbazepine Acetate 200 mg oral tablets carton packaging. The box shows the brand name, strength (200 mg), and dosage form (tablet). The labeler is Jubilant Cadista Pharmaceuticals Inc. The package contains 60 tablets.*

FDA Label Image

Structuralformula (Structure)

Chemical structure of eslicarbazepine acetate, showing its molecular framework with characteristic functional groups including an acetate ester and an amide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.